Dual role of lipoxin A4 in pneumosepsis pathogenesis

International Immunopharmacology

Volumn 17, Issue 2, 2013, Pages 283-292

  Sordi, Regina ^a   Menezes De Lima, Octávio ^b   Horewicz, Verônica ^a   Scheschowitsch, Karin ^a   Santos, Laís F ^a   Assreuy, Jamil ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

BML 111; BOC 2; FPR2 ALX; Sepsis; WRW(4)

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; CREATININE; FPR2 ALX RECEPTOR; LACTIC ACID; LIPOXIN A; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL LOAD; CELL MIGRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME INHIBITION; HEART; INFLAMMATION; KLEBSIELLA PNEUMONIAE; LACTATE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOCYTE MIGRATION; LUNG INFECTION; LUNG PARENCHYMA; MALE; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; SPLEEN; SURVIVAL RATE;

5(S),6(R),7-TRIHYDROXYHEPTANOIC ACID METHYL ESTER; 5(S),6(R)-LIPOXIN A(4); AHR; ARYL HYDROCARBON RECEPTOR; BAL; BML-111; BOC-2; BRONCHOALVEOLAR LAVAGE; CECAL LIGATION AND PUNCTURE; CLP; FORMYL PEPTIDE RECEPTOR-2; FPR2/ALX; LIPOXIN A(4); LIPOXYGENASES; LO; LXA(4); N-T-BOC-PHE-LEU-PHE-LEU-PHE; SEPSIS; TRP-ARG-TRP-TRP-TRP-TRP-CONH(2); WRW(4);

ANIMALS; BACTERIAL LOAD; CELL MOVEMENT; CELLS, CULTURED; DISEASE PROGRESSION; HEPTANOIC ACIDS; INTERLEUKIN-1BETA; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LIPOXINS; LUNG; MALE; MICE; OLIGOPEPTIDES; RECEPTORS, FORMYL PEPTIDE; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880181951     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.06.010     Document Type: Article

References (40)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10. (Pubitemid 32641789)
2. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002;28:108-21. (Pubitemid 34293822)
3. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009;101:36-47.
4. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001;163:316-21. (Pubitemid 32158505)
5. Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci U S A 1984;81:5335-9. (Pubitemid 14048742)
6. Serhan CN, Sheppard KA. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest 1990;85:772-80. (Pubitemid 20087480)
7. Schaldach CM, Riby J, Bjeldanes LF. Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry 1999;38:7594-600.
8. Maderna P, Godson C. Lipoxins: resolutionary road. Br J Pharmacol 2009;158:947-59.
9. Devchand PR, Arita M, Hong S, Bannenberg G, Moussignac RL, Gronert K, et al. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J 2003;17:652-9. (Pubitemid 37221150)
10. Aliberti J, Bafica A. Anti-inflammatory pathways as a host evasion mechanism for pathogens. Prostaglandins Leukot Essent Fatty Acids 2005;73:283-8. (Pubitemid 41253488)
11. Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, et al. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 2010;184:2611-9.
12. Serhan CN, Maddox JF, Petasis NA, Akritopoulou-Zanze I, Papayianni A, Brady HR, et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995;34:14609-15. (Pubitemid 3000720)
13. Maddox JF, Serhan CN. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med 1996;183:137-46.
14. Takano T, Clish CB, Gronert K, Petasis N, Serhan CN. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest 1998;101: 819-26. (Pubitemid 28096079)
15. Conte FP, Menezes-de-Lima Jr O, Verri Jr WA, Cunha FQ, Penido C, Henriques MG. Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects. Br J Pharmacol 2010;161:911 -24.
16. Karp CL, Flick LM, Park KW, Softic S, Greer TM, Keledjian R, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004;5:388-92. (Pubitemid 38500087)
17. Medeiros R, Rodrigues GB, Figueiredo CP, Rodrigues EB, Grumman Jr A, Menezes-de-Lima Jr O, et al. Molecular mechanisms of topical anti-inflammatory effects of lipoxin A(4) in endotoxin-induced uveitis. Mol Pharmacol 2008;74:154-61. (Pubitemid 351872166)
18. Menezes-de-Lima Jr O, Kassuya CA, Nascimento AF, Henriques MG, Calixto JB. Lipoxin A4 inhibits acute edema in mice: implications for the anti-edematogenic mechanism induced by aspirin. Prostaglandins Other Lipid Mediat 2006;80:123-35. (Pubitemid 44308413)
19. Bafica A, Scanga CA, Serhan C, Machado F, White S, Sher A, et al. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J Clin Invest 2005;115:1601-6. (Pubitemid 40814668)
20. Aliberti J, Serhan C, Sher A. Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med 2002;196:1253-62. (Pubitemid 35304190)
21. Sordi R, Menezes-De-Lima O, Della-Justina AM, Rezende E, Assreuy J. Pneumonia-induced sepsis in mice: temporal study of inflammatory and cardiovascular parameters. Int J Exp Pathol 2013;94:144-55.
22. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007;21: 325-32. (Pubitemid 46213480)
23. Machado FS, Aliberti J. Impact of lipoxin-mediated regulation on immune response to infectious disease. Immunol Res 2006;35:209-18. (Pubitemid 46020723)
24. Henson PM, Johnston Jr RB. Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins. J Clin Invest 1987;79:669-74. (Pubitemid 17050887)
25. Craciun FL, Schuller ER, Remick DG. Early enhanced local neutrophil recruitment in peritonitis-induced sepsis improves bacterial clearance and survival. J Immunol 2010;185:6930-8.
26. Spiller F, Orrico MI, Nascimento DC, Czaikoski PG, Souto FO, Alves-Filho JC, et al. Hydrogen sulfide improves neutrophil migration and survival in sepsis via K + ATP channel activation. Am J Respir Crit Care Med 2010;182:360-8.
27. Paula-Neto HA, Alves-Filho JC, Souto FO, Spiller F, Amêndola RS, Freitas A, et al. Inhibition of guanylyl cyclase restores neutrophil migration and maintains bactericidal activity increasing survival in sepsis. Shock 2011;35:17-27.
28. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
29. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM, et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cellsuppression and Th2 polarization in sepsis. J Exp Med 2007;204:1463-74. (Pubitemid 46919883)
30. Brudecki L, Ferguson DA, McCall CE, El Gazzar M. Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect Immun 2012;80:2026-34.
31. Arora M, Poe SL, Oriss TB, Krishnamoorthy N, Yarlagadda M, Wenzel SE, et al. TLR4/MyD88-induced CD11b + Gr-1 int F4/80+ non-migratory myeloid cells suppress Th2 effector function in the lung. Mucosal Immunol 2010;3:578-93.
32. Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moreno C, Scumpia PO, Laface DM, et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med 2011;17:281-92.
33. Pastula A, Marcinkiewicz J. Myeloid-derived suppressor cells: a double-edged sword? Int J Exp Pathol 2011;92:73-8.
34. Decker Y, McBean G, Godson C. Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321 N1 human astrocytoma cells. Am J Physiol Cell Physiol 2009;296:C1420-7.
35. Prescott D, McKay DM. Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am J Physiol Gastrointest Liver Physiol 2011;301:G487-97.
36. Wang YP, Wu Y, Li LY, Zheng J, Liu RG, Zhou JP, et al. Aspirin-triggered lipoxin A4 attenuates LPS-induced pro-inflammatory responses by inhibiting activation of NF-κB and MAPKs in BV-2 microglial cells. J Neuroinflammation 2011;8:95.
37. Walker J, Dichter E, Lacorte G, Kerner D, Spur B, Rodriguez A, et al. Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis. Shock 2011;36:410-6.
38. Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009;461: 1287-91.
39. Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev 2006;17(6):501-19. (Pubitemid 44793122)
40. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005;4:854-65. (Pubitemid 41553966)